Invention Grant
- Patent Title: 2,6,7 substituted purines as HDM2 inhibitors
-
Application No.: US14764616Application Date: 2014-02-04
-
Publication No.: US09682978B2Publication Date: 2017-06-20
- Inventor: Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Liping Yang
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Young Zhao; John C. Todaro
- International Application: PCT/US2014/014638 WO 20140204
- International Announcement: WO2014/123882 WO 20140814
- Main IPC: C07D473/30
- IPC: C07D473/30 ; C07D473/34 ; C07D473/00
Abstract:
The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
Public/Granted literature
- US20150368247A1 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS Public/Granted day:2015-12-24
Information query
